Global Oncology

Our Global Oncology organization integrates the expertise of Boston Biomedical, Tolero Pharmaceuticals, and their parent company, Sumitomo Dainippon Pharma, to advance a pipeline of innovative oncology compounds. With this new framework, we are leveraging the collective power of our research and development teams to expedite the discovery, development, and commercialization of novel treatment options. Our leadership structure ensures alignment across the integrated organization to accelerate the availability of new therapeutic options.

Global Oncology is also actively expanding research and discovery efforts through our External Innovation Hub, which is housed in Cambridge, MA at the offices of Boston Biomedical.

Leadership

Patricia S Andrews

Chief Executive Officer,
Boston Biomedical, Inc.
Global Head of Oncology

David J Bearss, PhD

Chief Executive Officer, Tolero Pharmaceuticals
Chief Scientific Officer and Global Head of Research

Edgar Braendle, MD, PhD

Chief Medical Officer,
Boston Biomedical, Inc.
Global Head of Development

Masashi Murata, PhD

Chief Strategic Officer,
Global Strategy and Planning